1800-123-9757 (Toll free)                022-49735550 (Landline) info@septalyst.com
  • Home
  • About Us
    • Company Profile
    • Awards & Recognition
    • Conference Participation
    • Annual Meets
    • Our Story
  • Products
    • NEPHROLOGY
    • Renal Transplant
    • Renal Medicines
    • Renal Nutrition
    • Cardio-Reno Protection
    • NEUROLOGY
    • Anti-Depressants
    • Neuro-Degeneration
    • Anti-Epileptics
    • Bipolar Disorder
    • Anti-Psychotics
    • Migraine
    • Stroke
    • Vertigo
    • Nerve Pain
    • Pain Relief
    • Neuro-Supplement
    • Other
    • CRITICAL CARE
    • Intensive Care
    • NEW LAUNCHES
  • Stockists
  • Careers
  • Partner With us
  • Contact Us
Search product here?
  • 27 July 2022
  • Business Others
Kidney Disease and Loss of Appetite

Why do CKD Patients Have a Poor Appetite?

Poor appetite is common in patients with chronic kidney disease (CKD), and these symptoms worsen as the disease progresses. The continuous decline of the glomerular filtration rate in CKD patients is associated with a significant reduction in food intake. Around one-third of chronic dialysis patients complain of a fair or poor appetite. And this is directly related to poor patient outcomes. A close association between appetite, malnutrition, and inflammation has been reported in patients undergoing hemodialysis.

Leptin inhibits food intake, stimulates energy expenditure, and modulates the activity of nitric oxide synthase (NOS). 28-amino acid peptide ghrelin, synthesized principally in the stomach is responsible for increasing food intake and body weight. Lower levels of acyl ghrelin and obestatin are found in Hemodialysis patients. Increased PTH levels also influence the appetite negatively.

Appetite Regulation

The factors influencing food intake are complex it involves metabolic signals (hunger and satiety). The hunger center is in the lateral hypothalamus containing dopaminergic neurotransmitters. The satiety center is in the ventromedial hypothalamus containing serotoninergic and adrenergic neurotransmitters.

The Consequences

Protein energy wasting is associated with adverse clinical outcomes, such as increased rates of hospitalization and death.

The Hunger Management in CKD

Counselling

Trained dietitians play a central role in helping patients and their families with food choices, meal schedules, and healthful eating habits.

Medications

Appetite stimulants, including megestrol, dronabinol, mirtazapine, and cyproheptadine, as adjunctive treatment options in addition to parenteral or oral nutritional supplementation, are recommended by The International Society of Renal Nutrition and Metabolism for CKD patients.

Increased PTH levels in patients with CKD are also associated with poor appetite. Calcium sensing receptor agonists like Cinacalcet are effective in reducing PTH value.

In patients in whom preventive measures in dietary intake, nutritional supplementation, administered orally, enterally, or parenterally, is effective in replenishing protein and energy stores and helps maintain adequate nutritional status. Alpha keto-analogs are helpful in protein deficiency.

In patients with ESRD on dialysis, there are protein catabolic processes, such as the unavoidable loss of amino acids (6–8 g per HD session) and albumin into the dialysate. IV amino acid supplements such as pure crystalline amino acid solution are highly beneficial without discomfort for HD patients.

BLOG CATEGORIES
  • Business Others6
RECENT BLOGS
  • Why do CKD Patients Have a Poor Appetite?
  • Carnosine and Gingko Biloba in Brain-Related Disorders
  • CKD and Anemia
USEFUL LINKS
  • Company Profile
  • Awards & Recognition
  • Conferences
  • Anuual Meets
  • Our Story
  • Contact Us
  • Blog
PRODUCT CATEGORIES
  • Renal Transplant
  • Renal Medicines
  • Renal Nutrition
  • Cardio-Reno Protection
  • Anti-Depressants
  • Neuro-Degeneration
  • Anti-Epileptics
  • Bipolar Disorder
  • Anti-Psychotics
PRODUCT CATEGORIES
  • Migraine
  • Stroke
  • Vertigo
  • Nerve Pain
  • Pain Relief
  • Neuro-Supplement
  • Other
  • Intensive Care
Usage Terms
  • Terms & Conditions
  • Privacy Policy
  • Cookies Policy
  • Disclaimer

Copyright © 2010 - 2025 Septalyst Lifesciences Private Limited.

Developed By Arine Solutions